Profile data is unavailable for this security.
About the company
Organogenesis Holdings Inc. is a regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. It offers a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Its advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier and native, cross-linked extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types. Sports Medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for management of open wounds in the surgical setting.
- Revenue in USD (TTM)433.14m
- Net income in USD4.95m
- Incorporated2018
- Employees862.00
- LocationOrganogenesis Holdings Inc85 Dan RdCANTON 02021-2810United StatesUSA
- Phone+1 (781) 575-0775
- Fax+1 (302) 655-5049
- Websitehttps://investors.organogenesis.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verrica Pharmaceuticals Inc | 5.12m | -67.00m | 307.97m | 100.00 | -- | 15.58 | -- | 60.10 | -1.46 | -1.46 | 0.113 | 0.466 | 0.0811 | -- | 2.09 | 51,240.00 | -106.07 | -55.75 | -126.60 | -78.33 | 85.44 | -- | -1,307.48 | -754.94 | 4.49 | -51.74 | 0.6914 | -- | -43.27 | -- | -173.59 | -- | 5.65 | -- |
| Fractyl Health Inc | 120.00k | -94.27m | 311.69m | 102.00 | -- | -- | -- | 2,597.40 | -1.97 | -1.97 | 0.0025 | -0.7881 | -- | -- | -- | 1,176.47 | -- | -- | -- | -- | 35.83 | -- | -64,242.50 | -- | 3.18 | -2.62 | 3.17 | -- | -- | -- | -48.15 | -- | -- | -- |
| Sutro Biopharma Inc | 153.73m | -106.79m | 313.16m | 302.00 | -- | 1.56 | -- | 2.04 | -1.79 | -1.79 | 2.56 | 2.45 | 0.3503 | -- | 7.12 | 509,043.00 | -24.34 | -25.48 | -29.77 | -29.75 | -- | -- | -69.47 | -113.71 | -- | -- | 0.0264 | -- | 126.84 | 31.96 | 10.41 | -- | 22.61 | -- |
| Anavex Life Sciences Corp | 0.00 | -43.16m | 316.13m | 40.00 | -- | 2.33 | -- | -- | -0.5357 | -0.5357 | 0.00 | 1.65 | 0.00 | -- | -- | 0.00 | -29.12 | -40.04 | -31.88 | -43.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 0.9857 | -- | -- | -- |
| Procaps Group SA | 414.10m | 52.20m | 318.16m | 5.50k | 5.41 | 8.08 | 4.57 | 0.7683 | 0.5209 | 0.5209 | 4.16 | 0.3491 | 0.854 | 1.87 | 3.38 | 75,290.18 | 10.77 | -- | 19.01 | -- | 55.04 | -- | 12.61 | -- | 0.9861 | -- | 0.8829 | -- | 0.0434 | -- | 142.18 | -- | -- | -- |
| Enanta Pharmaceuticals Inc | 73.62m | -138.24m | 320.94m | 145.00 | -- | 1.67 | -- | 4.36 | -6.56 | -6.56 | 3.50 | 9.07 | 0.1897 | -- | 4.79 | 507,737.90 | -35.63 | -14.56 | -40.03 | -15.62 | -- | -- | -187.77 | -54.96 | -- | -- | 0.0074 | -- | -8.07 | -17.45 | -9.91 | -- | 24.89 | -- |
| CorMedix Inc | 0.00 | -46.34m | 321.09m | 82.00 | -- | 4.57 | -- | -- | -0.9172 | -0.9172 | 0.00 | 1.28 | 0.00 | 0.00 | -- | 0.00 | -64.32 | -54.84 | -73.33 | -62.32 | -- | 6.18 | -- | -18,323.42 | 6.78 | -- | 0.00 | -- | -100.00 | -- | -56.02 | -- | 46.27 | -- |
| MeiraGTx Holdings PLC | 14.02m | -84.03m | 321.53m | 419.00 | -- | 2.30 | -- | 22.94 | -1.58 | -1.58 | 0.2483 | 2.17 | 0.0435 | -- | 0.8908 | 33,453.46 | -26.06 | -26.40 | -33.89 | -32.66 | -- | -- | -599.47 | -420.70 | -- | -91.62 | 0.3429 | -- | -11.95 | -- | 35.17 | -- | 12.37 | -- |
| Organogenesis Holdings Inc | 433.14m | 4.95m | 328.59m | 862.00 | 67.74 | 1.17 | 16.18 | 0.7586 | 0.0368 | 0.0368 | 3.27 | 2.12 | 0.9526 | 4.02 | 5.05 | 502,482.60 | 1.09 | 5.46 | 1.31 | 6.90 | 75.42 | 74.94 | 1.14 | 4.81 | 2.44 | 9.05 | 0.1989 | 0.00 | -3.94 | 17.49 | -68.16 | -- | 67.34 | -- |
| Atea Pharmaceuticals Inc | 0.00 | -135.96m | 333.52m | 75.00 | -- | 0.5951 | -- | -- | -1.63 | -1.63 | 0.00 | 6.65 | 0.00 | -- | -- | 0.00 | -21.55 | -5.90 | -22.46 | -6.98 | -- | -- | -- | -38.91 | -- | -- | 0.00 | -- | -- | -- | -17.30 | -- | -- | -- |
| Nautilus Biotechnology Inc | 0.00 | -67.44m | 336.96m | 167.00 | -- | 1.35 | -- | -- | -0.5402 | -0.5402 | 0.00 | 1.99 | 0.00 | -- | -- | 0.00 | -21.26 | -- | -21.85 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.93 | -- | -- | -- |
| Caribou Biosciences Inc | 34.48m | -102.07m | 340.50m | 158.00 | -- | 0.9051 | -- | 9.88 | -1.45 | -1.45 | 0.4675 | 4.17 | 0.0856 | -- | 17.14 | 218,208.90 | -25.33 | -- | -27.24 | -- | -- | -- | -296.05 | -- | -- | -19,343.17 | 0.00 | -- | 148.91 | -- | -2.66 | -- | -- | -- |
| Ventyx Biosciences Inc | 0.00 | -192.96m | 341.92m | 79.00 | -- | 1.18 | -- | -- | -3.29 | -3.29 | 0.00 | 4.12 | 0.00 | -- | -- | 0.00 | -59.46 | -- | -63.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -77.97 | -- | -- | -- |
| Ocugen Inc | 6.04m | -63.08m | 342.24m | 65.00 | -- | 8.41 | -- | 56.70 | -0.2616 | -0.2616 | 0.0247 | 0.1581 | 0.0697 | -- | -- | 92,861.54 | -72.85 | -83.56 | -91.66 | -97.79 | -- | -- | -1,045.03 | -2,921.94 | -- | -- | 0.0646 | -- | 142.60 | -- | 27.33 | -- | 39.08 | -- |
Data as of May 03 2024. Currency figures normalised to Organogenesis Holdings Inc's reporting currency: US Dollar USD
32.51%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 13.29m | 10.07% |
| Soleus Capital Management LP (Investment Management)as of 31 Dec 2023 | 8.96m | 6.79% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 5.29m | 4.01% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 4.65m | 3.52% |
| Acadian Asset Management LLCas of 31 Dec 2023 | 2.53m | 1.92% |
| DWS Investments (UK) Ltd.as of 31 Dec 2023 | 2.51m | 1.90% |
| Geode Capital Management LLCas of 31 Dec 2023 | 1.70m | 1.29% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 1.40m | 1.06% |
| Dimensional Fund Advisors LPas of 31 Dec 2023 | 1.39m | 1.05% |
| AQR Capital Management LLCas of 31 Dec 2023 | 1.19m | 0.90% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
